Clinical trials: Growth Disorders
HIV Infections, Peripheral Nervous System Disease
A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy
To assess the efficacy, safety, and tolerability of recombinant human nerve growth factor ( rhNGF ) in the treatment of HIV-associated sensory neuropathy.
- Trial name
- NCT00000842
- Testing
- Nerve Growth Factor, Recombinant Human
- Where
- 14 sites in United States
- Volunteers
- 270 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Heart Failure
Evaluation of the Effect of Human Recombinant Growth Hormone in Patients With Advanced Heart Failure
Prospective randomized, placebo controlled, clinical trial to evaluate the effect of human growth hormone supplementation compared with placebo to patients with severe heart failure for a duration of 6 months on exercise…
- Trial name
- NCT00182169
- Testing
- Human recombinant growth hormone
- Where
- Canada
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Hamilton Health Sciences Corporation
Myopia
Myopia Control Using Bright Light Therapy, Myopic Defocus and Atropine
The purpose of the study is to investigate the effect of bright light therapy, myopic defocus, atropine and the combination in myopia control in schoolchildren.
- Trial name
- NCT04923841
- Testing
- High intensity light box for bright light therapy and single vision spectacle lenses, High intensity light box for bright light therapy and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses, High intensity light box for bright light therapy and atropine 0.01% eye drop and and single vision spectacle lenses
- Where
- Hong Kong
- Volunteers
- 577 people, healthy volunteers welcome
- Sponsor
- The Hong Kong Polytechnic University
Carcinoma, Non-Small-Cell Lung
Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations
This trial was to explore whether intravenous vitamin C can prolong resistance time of Tyrosine Kinase Inhibitor(TKI) on lung adenocarcinoma patients with Epidermal Growth Factor Receptor(EGFR) mutations, and can benefit NSCLC…
- Trial name
- NCT03799094
- Testing
- Vitamin C, Tyrosine kinase inhibitor
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Clifford Hospital, Guangzhou, China
Asthma
Effect of Montelukast on the Expression and Variation of TGF-β for Children With Mild Persistent Asthma
The Objective of our research is to observe the effect of cysteinyl leukotriene receptor antagonist on the expression and variation of TGF-β1 levels and mRNA expression in children with mild persistent asthma in their plasma and…
- Trial name
- NCT00536705
- Testing
- montelukast
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Breast Cancer
Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer
To evaluate the efficacy and safety of adjuvant CDK4/6 inhibitors in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.
- Trial name
- NCT07180056
- Testing
- CDK4/6 inhibitor
- Where
- China
- Volunteers
- 229 people
- Sponsor
- Wenjin Yin
Metastatic Colorectal Cancer
Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC
The purpose of this study is to evaluate the preliminary efficacy and safety of NIS793 and other novel investigational combinations with standard of care (SOC) anti-cancer therapy vs SOC anti-cancer therapy for the second line…
- Trial name
- daNIS-3 (NCT04952753)
- Testing
- NIS793, Bevacizumab, Modified FOLFOX6
- Where
- 55 sites in United States, Australia and 15 more
- Volunteers
- 204 people
- Sponsor
- Novartis Pharmaceuticals
Fetal Growth Retardation
Epigenetic Markers in Growth Restricted Human Pregnancies: a Case-controlled Study
This study is carried out to discover if a baby with restricted growth in the womb is subject to specific fetal programming which predisposes to the metabolic syndrome(diabetes,hypertension,heart disease) in adulthood.We have…
- Trial name
- NCT00510380
- Where
- Singapore
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National University Hospital, Singapore
Wet Macular Degeneration
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of KSI-301 administered at 12, 16 and 20 weeks intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in…
- Trial name
- DAZZLE (NCT04049266)
- Testing
- KSI-301, Aflibercept
- Where
- 75 sites in United States, Czechia and 5 more
- Volunteers
- 559 people
- Sponsor
- Kodiak Sciences Inc
Non-Small-Cell Lung Carcinoma
A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy
The main purpose of this study is to determine whether nivolumab + chemotherapy is effective as compared to chemotherapy in the treatment of patients with EGFR mutation, NSCLC who failed first line (1L) or second-line (2L) EGFR…
- Trial name
- CheckMate722 (NCT02864251)
- Testing
- Nivolumab, Ipilimumab, Pemetrexed
- Where
- 109 sites in United States, Canada and 8 more
- Volunteers
- 367 people
- Sponsor
- Bristol-Myers Squibb
Cystic Fibrosis, Growth Failure
Baby Observational and Nutritional Study
Cystic fibrosis (CF) is a life-shortening disease that causes breathing and digestive problems, but can now be diagnosed at the time of birth. Lung function is very hard to measure in infants, but growth is not.
- Conditions
- Cystic Fibrosis, Growth Failure, Exocrine Pancreatic Insufficiency
- Trial name
- BONUS (NCT01424696)
- Where
- 28 sites in United States
- Volunteers
- 231 people
- Sponsor
- Seattle Children's Hospital
Lymphoma, Large-Cell, Anaplastic, Carcinoma, Non-Small-Cell Lung
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)
The purpose of this study is 2-fold: initially, in the dose escalation phase, the goal is to determine the safety profile of orally administered brigatinib, including: the maximum tolerated dose (MTD), dose limiting toxicities…
- Trial name
- NCT01449461
- Testing
- Brigatinib
- Volunteers
- 137 people
- Sponsor
- Ariad Pharmaceuticals
Postnatal Growth Disorder
Individualized Fortification of Breast Milk for Preterm Infants - A Pilot Study
To analyze the weight gain of very low birth weight infants during a minimum period of three weeks before 36 weeks postmenstrual age when infants are fed with breast milk that has been individually fortified.
- Trial name
- IFO Pilot (NCT01305642)
- Testing
- Individualized fortification of breast milk
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- McMaster Children's Hospital
Salivary Gland Cancer
Iressa Study in Patients With Salivary Gland Cancer
The goal of this clinical research study is to learn if ZD1839 (Iressa®, gefitinib can help to shrink or slow the growth of advanced, recurrent, or metastatic salivary gland cancer. The safety of this drug will also be studied.
- Trial name
- NCT00509002
- Testing
- Gefitinib
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer
RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor.
- Trial name
- NCT00030537
- Testing
- erlotinib hydrochloride
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Growth Hormone Deficiency
Molecular Basis of the Growth Axis in Short Stature
To examine the clinical genetic and biochemical characteristics of children with growth hormone deficiency.
- Trial name
- NCT00453245
- Where
- Israel
- Sponsor
- HaEmek Medical Center, Israel
Hypopituitarism, Hypogonadism
Testosterone and Growth Hormone for Bone Loss in Men
Deficiency of testosterone, growth hormone, or both hormones can result in osteoporosis. If either hormone is replaced, the condition of the bones improves.
- Conditions
- Hypopituitarism, Hypogonadism, Growth Hormone Deficiency
- Trial name
- NCT00080483
- Testing
- Testosterone plus somatropin, testosterone
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Pennsylvania
Adrenal Hyperplasia, Congenital
Growth Hormone (GH) in Congenital Adrenal Hyperplasia
Congenital adrenal hyperplasia (CAH) is a genetic rare disease, which alters the adrenal production of gluco and mineralo corticoids. The treatment consists in supplementing children using hydrocortisone.
- Trial name
- OPALE GH (NCT03162172)
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Hospices Civils de Lyon
Chronic Kidney Disease, Chronic Renal Insufficiency
Growth Hormone Treatment in Infants Aged 1 to 2 Years With Chronic Renal Insufficiency (CRI) and Growth Retardation.
This trial is conducted in Europe. Objective(s): To evaluate the effect of human growth hormone on infants aged 1 to 2 years with chronic renal insufficiency (CRI) and growth retardation despite an adequate dietary intake.
- Trial name
- NCT00184769
- Testing
- somatropin
- Where
- 20 sites in Portugal, Spain
- Volunteers
- 16 people
- Sponsor
- Novo Nordisk A/S
Scoliosis, Adolescent Idiopathic Scoliosis
Validation of a New Generation of Orthopedic Brace for Treating Adolescent Idiopathic Scoliosis by Using Growth Modulation
Adolescent Idiopathic Scoliosis affects 3-4% of the Canadian population, of which about 10% will need a brace treatment during pubertal growth spurt.
- Trial name
- NCT04889339
- Testing
- Test brace versus control brace: Immediate correction, Test brace versus control brace: Long-term correction
- Where
- Canada
- Volunteers
- 58 people
- Sponsor
- St. Justine's Hospital